The urgency to find treatments for the COVID-19 virus has allowed researchers to set aside institutional bureaucracy and companies to apply their technologies in new ways. One example of this is Scipher Medicine’s collaboration with Northeastern University’s Barabasi Labs, Harvard Medical School, and Network Science Institute. The company is using its artificial intelligence platform to help identify existing therapies that might be repurposed as treatments for COVID-19. We spoke to Alif Saleh, CEO of Scipher, about the collaboration, the approach Scipher is using to identify drug candidates, and how this might expand on the company’s business strategy.